<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080010</url>
  </required_header>
  <id_info>
    <org_study_id>yanghs2020</org_study_id>
    <nct_id>NCT05080010</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma</brief_title>
  <official_title>Three Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the&#xD;
      treatment of Stage I enucleated retinoblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a phase â…¢ open label interventional case series. Patients with Stage I&#xD;
      enucleated retinoblastoma will receive 3 cycles of chemotherapy(CEV) oon a monthly basis.&#xD;
      Patients will be followed for 60 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>five years</time_frame>
    <description>measure the disease-free survival rate at five years</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>3 cycles chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 cycles chemotherapy</intervention_name>
    <description>Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.</description>
    <arm_group_label>3 cycles chemotherapy</arm_group_label>
    <other_name>vincristine, carboplatin, etoposide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study.&#xD;
&#xD;
          -  Definite pathology signs of retinoblastoma, Stage I base on International&#xD;
             Retinoblastoma Staging System.&#xD;
&#xD;
          -  Received enucleation in the study eye.&#xD;
&#xD;
          -  Monocular retinoblastoma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous disease in the study eye.&#xD;
&#xD;
          -  Previous participation in any studies of investigational drugs within 1 month&#xD;
             preceding Day 0 (excluding vitamins and minerals).&#xD;
&#xD;
          -  History of chemical intervention for retinoblastoma in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huasheng Yang, M.D, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huasheng Yang, M.D, PHD</last_name>
    <phone>+8620-87331539</phone>
    <email>yanghs64@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huasheng Yang, M.D, PHD</last_name>
      <phone>+8620-87331539</phone>
      <email>yanghs64@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huasheng Yang</investigator_full_name>
    <investigator_title>Sun Yat-sen University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

